Shares of Vanda Pharmaceuticals Inc. VNDA were up 4.5% on May 15 after the company announced positive data from a second phase III study, which evaluated its neurokinin-1 receptor antagonist, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback